The most commonly used gene expression profile test, Oncotype DX®, used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers.
The most commonly used gene expression profile test, Oncotype DX®, used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers.